Genomma Lab (Mexico) Performance
| LABB Stock | MXN 25.40 0.17 0.67% |
Genomma Lab has a performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.15, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Genomma Lab are expected to decrease at a much lower rate. During the bear market, Genomma Lab is likely to outperform the market. Genomma Lab Internacional right now retains a risk of 2.11%. Please check out Genomma Lab jensen alpha, sortino ratio, maximum drawdown, as well as the relationship between the total risk alpha and treynor ratio , to decide if Genomma Lab will be following its current trending patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Genomma Lab Internacional are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Genomma Lab is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 2.1 B | |
| Total Cashflows From Investing Activities | -765.6 M |
Genomma |
Genomma Lab Relative Risk vs. Return Landscape
If you would invest 2,514 in Genomma Lab Internacional on December 30, 2024 and sell it today you would earn a total of 26.00 from holding Genomma Lab Internacional or generate 1.03% return on investment over 90 days. Genomma Lab Internacional is generating 0.0382% of daily returns and assumes 2.1095% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than Genomma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Genomma Lab Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genomma Lab's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genomma Lab Internacional, and traders can use it to determine the average amount a Genomma Lab's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0181
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LABB |
Estimated Market Risk
| 2.11 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Genomma Lab is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genomma Lab by adding it to a well-diversified portfolio.
Genomma Lab Fundamentals Growth
Genomma Stock prices reflect investors' perceptions of the future prospects and financial health of Genomma Lab, and Genomma Lab fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genomma Stock performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 20.43 B | |||
| Shares Outstanding | 1 B | |||
| Price To Earning | 13.61 X | |||
| Price To Book | 1.51 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 15.49 B | |||
| EBITDA | 2.84 B | |||
| Cash And Equivalents | 1.41 B | |||
| Cash Per Share | 1.40 X | |||
| Total Debt | 3.83 B | |||
| Debt To Equity | 0.61 % | |||
| Book Value Per Share | 10.98 X | |||
| Cash Flow From Operations | 1.47 B | |||
| Earnings Per Share | 1.30 X | |||
| Total Asset | 21.54 B | |||
About Genomma Lab Performance
Evaluating Genomma Lab's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Genomma Lab has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genomma Lab has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico, the United States, and Latin America. Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is based in Mexico City, Mexico. GENOMMA LAB operates under Drug ManufacturersSpecialty Generic classification in Mexico and is traded on Mexico Stock Exchange. It employs 1451 people.Things to note about Genomma Lab Internacional performance evaluation
Checking the ongoing alerts about Genomma Lab for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genomma Lab Internacional help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 29.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Genomma Lab's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genomma Lab's stock is overvalued or undervalued compared to its peers.
- Examining Genomma Lab's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genomma Lab's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genomma Lab's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genomma Lab's stock. These opinions can provide insight into Genomma Lab's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Genomma Stock Analysis
When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.